Syn­thet­ic DNA play­er Touch­light scores $60M round to more than triple man­u­fac­tur­ing ca­pac­i­ty as mR­NA gets hot

With the twin au­tho­riza­tions of Pfiz­er/BioN­Tech’s and Mod­er­na’s mR­NA vac­cines for Covid-19 late last year, the mar­ket for start­ing ma­te­ri­als for that type of shot has seen a big boost. One UK play­er with a new way to man­u­fac­ture DNA, a key pre­cur­sor to pro­duc­ing mR­NA, is cash­ing a siz­able check to scale up in a big way.

Touch­light has wran­gled $60 mil­lion in fi­nanc­ing to add 11 pro­duc­tion suites to its Lon­don site spe­cial­iz­ing in pro­duc­ing syn­thet­ic DNA it says can be pro­duced much faster than nor­mal plas­mid DNA, the com­pa­ny said Wednes­day.

The ex­pan­sion will en­able Touch­light to triple pro­duc­tion of its pro­pri­etary vec­tor, dbD­NA or what it calls “dog­gy­bone” DNA, by Q1 2022. The vec­tor can be used in ap­pli­ca­tions as wide as mR­NA vac­cines and gene ther­a­pies, and Touch­light said its es­ti­mat­ed ca­pac­i­ty could be enough to sup­ply up to 1 bil­lion Covid-19 shot dos­es per month.

Adding that ca­pac­i­ty will take Touch­light’s foot­print at its Lon­don head­quar­ters to more than 7,500 square feet and will re­quire hir­ing at least 60 new em­ploy­ees by the time the ex­pan­sion is op­er­a­tional. The com­pa­ny’s to­tal pro­duc­tion suites will num­ber 15 af­ter the in­vest­ment. The round was led by Brid­ford In­vest­ments Lim­it­ed.

Some of Touch­light’s move is ob­vi­ous­ly meant to ad­dress the man­u­fac­tur­ing crunch for Covid-19 vac­cines, but the firm doesn’t see a ma­jor slow­down in de­mand once the pan­dem­ic comes to a close.

“The ge­net­ic med­i­cine in­dus­try is boom­ing, and we don’t ex­pect any slow­ing down of de­mand,” said Karen Fall­en, CEO of Touch­light DNA Ser­vices, in a state­ment. “Avail­abil­i­ty of plas­mid DNA has be­come a bot­tle­neck which we are ide­al­ly po­si­tioned to ad­dress.”

Fall­en, a for­mer bi­o­log­ics man­u­fac­tur­ing head at Lon­za, came on board in Oc­to­ber as the firm was look­ing to rapid­ly scale up giv­en an in­crease in de­mand. At Lon­za, Fall­en served as pres­i­dent of mam­malian and mi­cro­bial de­vel­op­ment and man­u­fac­tur­ing and guid­ed 4,500 work­ers at 10 sites spread over three con­ti­nents.

In Feb­ru­ary, Fall­en told End­points News she chose to jump to the rel­a­tive un­known Touch­light af­ter de­cid­ing she want­ed a chance to try some­thing new.

“It was my time, I think, just to think about what do I want to do in the last 10 to 15 years of my ca­reer,” she said. “And I de­cid­ed ac­tu­al­ly that I just want­ed to do some­thing dif­fer­ent. I learned every­thing that I know at Lon­za, and had a fan­tas­tic time (there). It’s a bril­liant com­pa­ny — but I just thought I want­ed to do some­thing dif­fer­ent.”

The com­pa­ny’s al­ter­na­tive to plas­mid DNA has re­ceived re­newed in­ter­est giv­en the ap­provals of mR­NA vac­cines for Covid-19 from Pfiz­er/BioN­Tech and Mod­er­na. To make mR­NA vac­cines, man­u­fac­tur­ers first need to pro­duce bulk amounts of DNA, which they then mix with ar­ti­fi­cial en­zymes that trans­late the code in­to mR­NA.

Spe­cial re­port: Meet 20 ex­tra­or­di­nary women who are su­per­charg­ing bio­phar­ma R&D

Even though many biopharma leaders have come together in recent years to address its gender gap, the consensus is clear: We still have a long way to go.

Companies this year were 2.5 times more likely than last year to have a diversity and inclusion program in place, according to a recent BIO survey, but women are still largely absent from executive roles. Getting women to enter the industry isn’t the problem — studies show that they represent just under half of all biotech employees around the world. But climbing through the ranks can be challenging, as women still report facing stereotypes, and, unfortunately, harassment.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 125,100+ biopharma pros reading Endpoints daily — and it's free.

Op­ti­miz­ing Oral Drug De­liv­ery us­ing Zy­dis® Oral­ly Dis­in­te­grat­ing Tablet Tech­nol­o­gy to Ad­dress Pa­tient Chal­lenges


Patients prefer oral dosing, but swallowing tablets can be a challenge for many patients.
The Zydis® orally disintegrating tablet (ODT) platform addresses challenges associated with oral dosing, expanding benefits for patients and options for healthcare providers.
A strong growth trajectory is expected for ODTs given therapeutic innovation and continued technology development.

Many patients prefer conventional tablets for the administration of medications, but some geriatric and pediatric patients and those with altered mental status and physical impairments find swallowing tablets to be difficult. Orally disintegrating tablets (ODTs), which dissolve completely without chewing or sucking, offer a patient-friendly dosage form for the administration of small-molecule drugs, peptides and proteins. With the potential for multiple sites of drug absorption, often faster onset action for the active pharmaceutical ingredient (API), and potentially greater bioavailability, ODTs are an attractive option for drug developers considering first-to-market formulations or product line extensions of existing drugs with compatible API. In this report, we look at how innovation in the industry-leading Zydis ODT platform is expanding oral formulation options and bringing benefits to patients.

Read the full sponsored article

Please signup to continue — it's fast and free. This article is sponsored by Catalent and produced by Endpoints Studio.

Geoffrey Porges (SVB Leerink)

The 2022 wave com­ing? Top an­a­lyst says Big Phar­ma will have more than $1T avail­able to sat­is­fy its grow­ing ap­petite for biotech M&A

All through this year you could practically feel the frustration of the biotech investor class as M&A activity continued to drag behind expectations — or desires. Buyouts of public companies provide the essential juice for keeping stocks lively, and there’s been a notable lack of juice in 2021.

So is all that about to change, big time?

SVB Leerink’s Geoffrey Porges, a longtime student of biotech M&A, thinks so. In a lengthy analysis he put out last week, Porges totted up the cash flow of the major pharmas and determined that there was a good long list of industry buyers who would have around a half trillion dollars of cash to play with in 2022. Leverage that up with added debt and you could get that deal cache to $1.6 trillion.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Róbert Wessman, Alvotech chairman and founder

Ice­landic bil­lionare's biosim­i­lar com­pa­ny rais­es $450M, preps for Nas­daq launch with SPAC merg­er

As Icelandic billionaire Róbert Wessman tries to take down AbbVie’s megablockbuster Humira in court, he’s also taking his biosimilar upstart to the big time with a $2.25 billion SPAC merger, Nasdaq launch and $450 million raise announced early Tuesday.

While Wessman’s Alvotech has not won FDA approval for any of its biosimilar candidates yet, the company was the first to file with the FDA for approval of its high-concentration Humira biosimilar and to have successfully conducted a switching study in support of a highly-coveted interchangeability designation. But other companies like Amgen, Boehringer Ingelheim and Pfizer have since caught up ahead of the launches of their own Humira biosimilar competitors in 2023.

Gary Glick, Odyssey Therapeutics founder

Al­ways busy, Gary Glick re­cruits Or­biMed in a mas­sive $218M Se­ries A for enig­mat­ic da­ta sci­ence biotech

Gary Glick is back at it again, founding yet another biotech company. And by the sheer size of its first raise, this may be the biggest one yet.

Glick has assembled what he calls an all-star roster and recruited one of the biggest healthcare investors in OrbiMed to put together a massive $218 million Series A for his newest venture, Odyssey Therapeutics. The launch, announced Tuesday morning and co-led by SR One Capital Management, comes not three months after Glick sold First Wave Bio to AzurRx for $229 million.

Mar­ket­ingRx Matchup: How Ab­b­Vie and Bio­haven ads rank in head-to-head mi­graine chal­lenge

Are you ready to rumble? DTC brands that is. MarketingRx is launching a new monthly feature today called MarketingRx Matchup. We’re pitting two pharma brands’ DTC advertising in the same therapeutic category against each other to find out what consumers and patients really think.

Market research company Leger is handling the polling and analysis each month, and I’ll be writing up the results — along with my own take — inside MRx on the first Tuesday of the month.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 125,100+ biopharma pros reading Endpoints daily — and it's free.

Wendy Lund, Organon chief communications officer

Q&A: Organon chief com­mu­ni­ca­tions of­fi­cer Wendy Lund talks about the Mer­ck spin­off, women’s health and why it mat­ters

One of Wendy Lund’s earliest jobs was head of marketing at Planned Parenthood. As the youngest person on its management team, she introduced them to emerging new technologies, and in return, she learned the importance of fighting for what you believe in.

Now as chief communications officer at Organon, the women’s health company recently spun off by Merck, Lund is keeping that point top of mind. That’s in part because women’s health hasn’t been a spotlight therapy area for Big Pharma in years. Several companies have spun off, sold or at least considered selling women’s health assets to focus on “core” products.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 125,100+ biopharma pros reading Endpoints daily — and it's free.

Mar­ket­ingRx roundup: Pfiz­er re-ups pneu­mo­nia ads as Mer­ck threat looms; Re­al Chem­istry founder CEO Jim Weiss steps back

Every autumn, leaves fall from the trees and people start holiday shopping – and for the last few years Pfizer debuts a new “Know Pneumonia” awareness TV ad. This year the commercial, launched a week ago, features different people who talk about why they got vaccinated against pneumococcal pneumonia. Actors portray a young female firefighter with asthma, a mechanic with heart disease and an older woman with her grandchild. A Pfizer spokesperson declined comment on the latest iteration of the long-running campaign.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 125,100+ biopharma pros reading Endpoints daily — and it's free.

Mer­ck pumps the brakes on two more PhI­II tri­als for its lead an­ti-HIV drug

After trial investigators flagged a drop in immune cell counts that an external committee determined was related to treatment last month, Merck has been pausing HIV-related Phase II and III trials ever since.

On Monday, the biopharma company announced it’s pausing enrollment in two of its Phase III trials evaluating its leading anti-HIV drug candidate, which is the once-monthly, oral islatravir.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 125,100+ biopharma pros reading Endpoints daily — and it's free.